GlassScriptPhysician profile
Paula Kay Deanda
NPI 1831178912
$6,556.09
in general payments reported to CMS, 2019-2025
13 companies · $581 in 2025
The $581 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $620 · 2022: $621 · 2023: $431 · 2024: $4,302 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,314.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Koya Medical, INC. | $3,900.00 | 2024 | Dayspring, Koya Medical |
| Astrazeneca Pharmaceuticals LP | $742.27 | 2021-2024 | Tezspire, Saphnelo |
| Neurocrine Biosciences, INC. | $265.24 | 2024-2025 | Ingrezza |
| Actelion Pharmaceuticals US, INC. | $252.80 | 2022-2023 | Opsumit, Uptravi |
| Abbott Laboratories | $242.62 | 2022 | |
| Cequr Corporation | $194.07 | 2024 | Cequr Simplicity |
| Abbvie INC. | $185.34 | 2021-2023 | |
| Medtronic, INC. | $172.09 | 2025 | Corevalve Evolut R |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.95 | 2025 | Caplyta |
| Genentech USA, INC. | $125.00 | 2021 | |
| Paratek Pharmaceuticals, INC. | $124.98 | 2022 | |
| Averitas Pharma INC. | $121.83 | 2023 | Qutenza |
| Janssen Biotech, INC. | $103.90 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Deanda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.